论文部分内容阅读
目的检测膀胱移行细胞癌(bladder transitional cell carcinoma,BTCC)和癌旁正常膀胱组织中整合素连接激酶(ILK)蛋白和mRNA的表达,探讨其在BTCC发生、发展中的作用。方法利用免疫组织化学S-P法检测56例BTCC和30例癌旁正常膀胱组织中ILK蛋白的表达,同时运用逆转录聚合酶链反应法检测这些组织标本中ILK mRNA的表达,并与临床病理资料进行相关性分析。结果56例BTCC中,ILK蛋白阳性表达率为53.6%(30/56),ILK mRNA阳性表达率为58.9%(33/56);而30例癌旁正常膀胱组织中ILK蛋白阳性表达率为10%(3/30),ILK mRNA表达阳性率为13.3%(4/30),ILK mRNA和蛋白在癌组织和癌旁正常膀胱组织表达有显著差异(P<0.01)。临床病理资料的相关性分析显示,BTCC中,ILK mRNA和蛋白的表达分布与病理分级有相关性(P<0.05),但与临床分期无相关性(P>0.05)。结论ILK基因转录和蛋白表达可能参与BTCC的发生过程,ILK可能成为早期发现BTCC的一个肿瘤标志物和治疗BTCC的新靶点。
Objective To detect the expression of ILK protein and mRNA in bladder transitional cell carcinoma (BTCC) and adjacent normal bladder tissues, and to explore its role in the occurrence and development of BTCC. Methods Immunohistochemical SP method was used to detect the expression of ILK protein in 56 cases of BTCC and 30 cases of adjacent normal bladder tissues. Meanwhile, the expression of ILK mRNA in these tissues was detected by reverse transcription-polymerase chain reaction (RT-PCR) Correlation analysis. Results The positive rate of ILK protein was 53.6% (30/56) and the positive rate of ILK mRNA was 58.9% (33/56) in 56 cases of BTCC. The positive rate of ILK protein in 30 cases of adjacent normal bladder tissue was 10 % (3/30). The positive rate of ILK mRNA expression was 13.3% (4/30). The expression of ILK mRNA and protein in cancer tissue and adjacent normal bladder tissue was significantly different (P <0.01). Correlation analysis of clinicopathological data showed that the expression of ILK mRNA and protein in BTCC was correlated with pathological grade (P <0.05), but not with clinical stage (P> 0.05). Conclusion ILK gene transcription and protein expression may be involved in the pathogenesis of BTCC. ILK may be a tumor marker for early detection of BTCC and a new target for treatment of BTCC.